Literature DB >> 15116366

Botulinum toxins in neurological disease.

Cynthia L Comella1, Seth L Pullman.   

Abstract

Botulinum toxins are among the most potent neurotoxins known to humans. In the past 25 years, botulinum toxin has emerged as both a potential weapon of bioterrorism and as a powerful therapeutic agent, with growing applications in neurological and non-neurological disease. Botulinum toxin is unique in its ability to target peripheral cholinergic neurons, preventing the release of acetylcholine through the enzymatic cleavage of proteins involved in membrane fusion, without prominent central nervous system effects. There are seven serotypes of the toxin, each with a specific activity at the molecular level. Currently, serotypes A (in two preparations) and B are available for clinical use, and have been shown to be safe and effective for the treatment of dystonia, spasticity, and other disorders in which muscle overactivity gives rise to symptoms. This review focuses on the pharmacology, electrophysiology, immunology, and application of botulinum toxin in selected neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15116366     DOI: 10.1002/mus.20033

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

1.  Synaptic vesicle chips to assay botulinum neurotoxins.

Authors:  Géraldine Ferracci; Raymond Miquelis; Shunji Kozaki; Michael Seagar; Christian Lévêque
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients.

Authors:  Steven E Lo; Axel J Rosengart; Roberta L Novakovic; Un Jung Kang; Darshan N Shah; Mohsin A Khan; Arif Dalvi; Fernando D Goldenberg; R Loch Macdonald; Jeffrey I Frank
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Authors:  Bing Li; Steven C Cardinale; Michelle M Butler; Ramdas Pai; Jonathan E Nuss; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Bioorg Med Chem       Date:  2011-10-26       Impact factor: 3.641

5.  Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Authors:  James C Burnett; Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald Moir; Sina Bavari; Terry Bowlin
Journal:  Open Access Bioinformatics       Date:  2010-04-01

6.  Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution.

Authors:  Christina Vessely; Tia Estey; Theodore W Randolph; Ian Henderson; Julianne Cooper; Rajiv Nayar; Latoya Jones Braun; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

7.  Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors.

Authors:  Gordon Ruthel; James C Burnett; Jonathan E Nuss; Laura M Wanner; Lyal E Tressler; Edna Torres-Melendez; Sarah J Sandwick; Cary J Retterer; Sina Bavari
Journal:  Toxins (Basel)       Date:  2011-03-15       Impact factor: 4.546

8.  A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.

Authors:  Ronaldo Alvarenga Álvares; Ivana Duval Araújo; Marcelo Dias Sanches
Journal:  BMC Urol       Date:  2014-08-14       Impact factor: 2.264

Review 9.  Contribution of Single-Fiber Evaluation on Monitoring Outcomes Following Injection of Botulinum Toxin-A: A Narrative Review of the Literature.

Authors:  Hélène Moron; Corine Gagnard-Landra; David Guiraud; Arnaud Dupeyron
Journal:  Toxins (Basel)       Date:  2021-05-17       Impact factor: 4.546

10.  Neurologic uses of botulinum neurotoxin type A.

Authors:  John P Ney; Kevin R Joseph
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.